LOS ANGELES—HemaCare Corporation (OTCBB:HEMA) a leader in cell and tissue collection, processing and cell therapy solutions, announced that it has expanded its offering of stem cell rich peripheral blood through the addition of a new protocol.
This type of blood, referred to among researchers as “mobilized peripheral blood,” is collected following a procedure that induces the bone marrow to produce more white cells into the periphery. These white cells can then be collected with a routine leukapheresis and provided to researchers within 24 hours.